Table 3.
Summary of clinicopathological parameters in human breast cancers
| Case | Age | Gender | Subtype | TN | Stage | Recurrence | Histopathological diagnosis |
|---|---|---|---|---|---|---|---|
| 1 | 58 | Female | Luminal B | T4bN1 | IIIB | − | Scirrhous carcinoma |
| 4 | 46 | Female | Luminal B | T2N0 | IIA | − | Scirrhous carcinoma |
| 15 | 76 | Female | Luminal B | T1N0 | I | − | Invasive lobular carcinoma |
| 28 | 48 | Female | Luminal B | T2N1 | IIB | + | Solid‐tubular carcinoma |
| 39 | 51 | Female | Luminal B | T3N1 | IIIA | − | Scirrhous carcinoma |
| 55 | 72 | Female | Luminal B | T2N0 | IIA | − | Scirrhous carcinoma |
| 2 | 74 | Female | Luminal A | T2N0 | IIA | − | Solid‐tubular carcinoma |
| 6 | 36 | Female | HER2 | T2N1 | IIB | + | Scirrhous carcinoma |
| 10 | 69 | Female | Triple negative | T1N1 | IIA | − | Solid‐tubular carcinoma |
| 11 | 45 | Female | Luminal/HER2 | T1N0 | I | − | Scirrhous carcinoma |
| 12 | 75 | Female | Luminal/HER2 | T1N2 | IIB | − | Solid‐tubular carcinoma |
| 13 | 72 | Female | Luminal A | T1N0 | I | − | Scirrhous carcinoma |
| 16 | 51 | Female | Luminal A | T1N1 | IIA | − | Papillotubular carcinoma |
| 17 | 60 | Female | Luminal A | T2N0 | IIA | − | Papillotubular carcinoma |
| 18 | 43 | Female | Luminal B | T2N0 | IIA | − | Papillotubular carcinoma |
| 19 | 66 | Female | Luminal A | T1N1 | IIA | − | Scirrhous carcinoma |
| 20 | 79 | Female | Luminal A | T1N0 | I | − | Solid‐tubular carcinoma |
| 22 | 58 | Female | Luminal A | T1N1 | IIA | − | Scirrhous carcinoma |
| 23 | 84 | Female | Luminal B | T1N0 | I | − | Scirrhous carcinoma |
| 24 | 62 | Female | Luminal A | T2N0 | IIA | − | Scirrhous carcinoma |
| 25 | 63 | Female | Luminal A | T2N0 | IIA | + | Scirrhous carcinoma |
| 26 | 49 | Female | Luminal B | T1N1 | IIA | − | Solid‐tubular carcinoma |
| 27 | 48 | Female | Luminal B | T2N0 | IIA | − | Scirrhous carcinoma |
| 29 | 57 | Female | Luminal B | T2N1 | IIB | − | Mucinous carcinoma |
| 30 | 61 | Female | Luminal A | T2N1 | IIB | − | Scirrhous carcinoma |
| 31 | 64 | Female | Luminal A | T2N1 | IIB | − | Scirrhous carcinoma |
| 32 | 52 | Female | Triple negative | T2N0 | IIA | − | Solid‐tubular carcinoma |
| 33 | 69 | Female | Triple negative | T2N0 | IIA | − | Papillotubular carcinoma |
| 34 | 51 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 35 | 46 | Female | Triple negative | T2N0 | IIA | + | Solid‐tubular carcinoma |
| 37 | 62 | Female | Triple negative | T1N0 | I | − | Scirrhous carcinoma |
| 38 | 53 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 40 | 42 | Female | Luminal B | T2N1 | IIB | − | Papillotubular carcinoma |
| 41 | 68 | Female | Luminal B | T1N0 | I | − | Solid‐tubular carcinoma |
| 42 | 57 | Female | Triple negative | T2N1 | IIB | + | Scirrhous carcinoma |
| 43 | 79 | Female | Triple negative | T2N0 | IIA | − | Papillotubular carcinoma |
| 44 | 51 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 46 | 64 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 47 | 63 | Female | Luminal A | T1N0 | I | − | Scirrhous carcinoma |
| 48 | 73 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 49 | 33 | Female | Luminal B | T1N0 | I | − | Scirrhous carcinoma |
| 50 | 58 | Female | Luminal B | T2N0 | IIA | − | Solid‐tubular carcinoma |
| 52 | 74 | Female | Luminal B | T4bN1 | IIIB | + | Scirrhous carcinoma |
| 53 | 46 | Female | Luminal B | T2N0 | IIA | − | Papillotubular carcinoma |
| 54 | 70 | Female | Luminal A | T1N0 | I | − | Papillotubular carcinoma |
| 56 | 68 | Female | HER2 | T2N0 | IIA | − | Mucinous carcinoma |
Clinicopathological parameters of 46 invasive breast cancer patients are shown followed by Table 2.